**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 60-year-old man exhibited a lack of drug effect during treatment with gammaglobulin for rhabdomyolysis.

The man was hospitalised with a 6-day history of cough and fever up to 38.3°C in February 2020. Then, he was diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). He started receiving an off-label treatment with moxifloxacin, lopinavir, interferon nebulization and an unspecified antitussive along with nutritional support and oxygen inhalation. On day 6 after admission, he still had an intermittent fever. Hence, off-label meropenem and methylprednisolone were added to his treatment regimen. On hospital day 7, his fever abated. However, his creatine kinase, CRP, lactate dehydrogenase, ALT and AST were also found increased. Based on various findings a diagnosis was confirmed with rhabdomyolysis. Therefore, in addition to the ongoing treatments, he was immediately treated with gammaglobulin \[*route and dosage not stated*\], hydration, alkalization, symptomatic supportive therapy and plasma transfusion. Despite receiving treatment, the laboratory index continuously increased. Further, pulmonary lesions were found to be substantially deteriorated.

The man was continued on moxifloxacin, lopinavir, aggressive fluid therapy and maintained the acid-base balance. His condition gradually improved including biochemistry and blood gas indicators. Additionally, he reported less pain and fatigue in his lower limbs. Moreover, on hospital day 12, his SARS-CoV-2 test was found negative. His symptoms improved daily and he was able to freely move his lower limbs.
